Video

Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG

“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.

In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.

Related Videos
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
William Furuyama, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman talking with doctor | Image Credit: © LuneVA/peopleimages.com - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.